• Brechka N. М. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Kozar V. V. National University of Pharmacy, Kharkiv, Ukraine
  • Bondarenko V. O. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Morozenko D. V. National University of Pharmacy, Kharkiv, Ukraine
  • Korenyeva Ye. M. SI «V. Danilevsky Institute of Endocrine Pathology Problems of NAMS of Ukraine», Kharkiv, Ukraine
  • Leontieva F. S. Sytenko Institute of Spine and Joint Pathology NAMS of Ukraine, Kharkiv, Ukraine



benign prostatic hyperplasia, C-reactive protein, sedimentation rate of erythrocytes, connective tissues, androgens, Сhondroitin sulfate


Benign prostatic hyperplasia (BPH) is a common disease which affects 50-80% of the male population
in old age. Based on the important role of chronic inflammation in the pathogenesis of BPH the concept of
its pharmacological treatment has also changed and an important property of drugs is the presence of antiinflammatory
effects. The purpose of the work was to evaluate the effect of Chondroitin sulfate, Bioglobin-U
and Tribestan on inflammation in experimental benign prostatic hyperplasia and in comparison with the
effects of other prostatoprotectors. BPH was caused by intraperitoneal administration of sulpiride (Eglonil)
at a dose of 40 mg/kg of animal body weight during 30 days. The model represents the development of lateral
parts hyperplasia of the prostate, which correlates with similar pathological changes in the human prostate.
After rats' BPH were given Chondroitin sulphate at a dose of 60 mg/kg, Chondroitin sulphate in combination
with Tribestan at a dose of 60 mg /kg, Tribestan (manufactured by Sopharma, Bulgaria) at a dose of 60 mg/kg,
and Bioglobin-U (a proteinised water-salt extract from a human placenta including polypeptides 3.5–7 %, amino
acids 50–60 %, amino sugars 4–5 %, hexuronic acids 8–9 %, produced by CJSC Biolik, Kharkiv) at a dose
of 200 μl/kg. The comparison drug was Prostaplant forte produced by Schwabe company, Germany. The drugs
were administered from the 30th to the 51st day of the experiment after completion of BPH modeling. The level
of C-reactive protein (CRP), sedimentation rate of erythrocytes (SRE), and white blood cell count have been
studied. It is proved that the model of prostatic hyperplasia is characterized by an increase in the number of
leukocytes and SRE and CRP concentration and the degree of their growth can be attributed to manifestations
of chronic inflammation. The studied drugs showed pronounced anti-inflammatory properties and this is
confirmed by a decrease of leukocytes number and SRE and the concentration of CRP in rats with experimental
benign prostatic hyperplasia. According to the results of a study of Сhondroitin sulfate, Bioglobin-U had
more pronounced antiinflammatory properties. Chondroitin sulfate reduced SRE more effectively than the
comparison drug Prostaplant forte. The studied preparations of Сhondroitin sulfate and Bioglobin-U which have
pronounced anti-inflammatory properties can be recommended for use in benign prostatic hyperplasia to reduce
the manifestations of inflammation.


Kardasevic A, Milicevic S. Med Arch 2016; 70(6): 449-452. doi:

Zattoni F, Ficarra V, Novara G. Urologia 2017; 84(3):153-157. doi:

Bojko AI, Shmulichenko OV. Ukr Med Chasopys 2017;4(120), available at:


Sajdakova NO, Stus’ VP, Dmytryshyn SP, et al. Urologija 2018: 5-12. doi:

Robert G, De La Taille A, Descazeaud A. Prog Urol 2018; 28(15): 803-812. doi:

Meshkov IO, Kulchavenya EV, Shevchenko SY, Neimark AI. Urologiia 2018; (4): 72-80.

Shimizu S, Shimizu T, Higashi Y, Saito M. Nihon Yakurigaku Zasshi 2019; 154(5): 250-254. doi:

Kohnen PW, Drach GW. J Urol 1979; 121(6): 755-760.

Nickel JC, Freedland SJ, Castro-Santamaria R, Moreira DM. J Urol 2017; 198(1): 122-128. doi:

Hu J, Zhang L, Zou L, et al. Int J Urol 2015; 22(12):1138-1142. doi:

Robert G, Salagierski M, Schalken JA, de La Taille A. Prog Urol 2010; 20(6): 402-407. doi:

Pigat N, Reyes-Gomez E, Boutillon F, et al. Front Pharmacol 2019; 29;10: 311. doi:

Van Coppenolle F, Le Bourhis X, Carpentier F, et al. Prostate 2000; 43(1): 49-58. doi:<49::AID-PROS7>3.0.CO;2-J.

Patent 38911. Sposib vyznachennja koncentracii’ S-reaktyvnogo bilka ekspres-metodom.

Wegner KA, Mueller BR, Unterberger CJ, et al. J Pathol 2019. doi:

Urios A, Ordoño F, García-García R, et al. Sci Rep 2019;9(1): 17119. doi:

Rohrmann S, De Marzo AM, Smit E, et al. Prostate 2005; 62(1): 27-33.

Shun-Fa Hung, Shiu-Dong Chung, Hann-Chorng Kuo. PLoS One 2014; 9(1): e85588. doi:

Iczkowski KA. Surg Pathol Clin 2018; 11(4): 687-712.doi:




How to Cite

Brechka, N., Kozar, V. V., Bondarenko, V. O., Morozenko, D. V., Korenyeva, Y. M., & Leontieva, F. S. (2020). THE INFLAMMATORY PROCESS CORRECTION IN RATS WITH BENIGN PROSTATIC HYPERPLASIA. Problems of Endocrine Pathology, 71(1), 98-104.

Most read articles by the same author(s)